Evidence map›Paper›PMID 23874462›Full record

ArticlePloS one2013

Dry-coated live viral vector vaccines delivered by nanopatch microprojections retain long-term thermostability and induce transgene-specific T cell responses in mice.

Frances E Pearson, Celia L McNeilly, Michael L Crichton, Clare A Primiero, Sally R Yukiko, Germain J P Fernando, Xianfeng Chen, Sarah C Gilbert, Adrian V S Hill, Mark A F Kendall

Abstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Nanotechnology, equity and global health.Nature nanotechnology · 2021
    Article
  11. Progress in microneedle array patch (MAP) for vaccine delivery.Human vaccines & immunotherapeutics · 2021
    Article
  12. Review
  13. Review
  14. Article
  15. Microneedles coated with peanut allergen enable desensitization of peanut sensitized mice.Journal of controlled release : official journal of the Controlled Release Society · 2019
    Article
  16. Article
  17. Microneedle Coating Methods: A Review with a Perspective.The Journal of pharmacology and experimental therapeutics · 2019
    Review
  18. Article
  19. Development of a thermostable microneedle patch for polio vaccination.Drug delivery and translational research · 2019
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Frances E PearsonDelivery of Drugs and Genes Group (D2G2), Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Queensland, Australia.
Celia L McNeilly
Michael L Crichton
Clare A Primiero
Sally R Yukiko
Germain J P Fernando
Xianfeng Chen
Sarah C Gilbert
Adrian V S Hill
Mark A F Kendall

Funding

Medical Research Council G0600311Wellcome Trust 090532
6 · The paper itself

Abstract

The disadvantages of needle-based immunisation motivate the development of simple, low cost, needle-free alternatives. Vaccine delivery to cutaneous environments rich in specialised antigen-presenting cells using microprojection patches has practical and immunological advantages over conventional needle delivery. Additionally, stable coating of vaccine onto microprojections removes logistical obstacles presented by the strict requirement for cold-chain storage and distribution of liquid vaccine, or lyophilised vaccine plus diluent. These attributes make these technologies particularly suitable for delivery of vaccines against diseases such as malaria, which exerts its worst effects in countries with poorly-resourced healthcare systems. Live viral vectors including adenoviruses and poxviruses encoding exogenous antigens have shown significant clinical promise as vaccines, due to their ability to generate high numbers of antigen-specific T cells. Here, the simian adenovirus serotype 63 and the poxvirus modified vaccinia Ankara--two vectors under evaluation for the delivery of malaria antigens to humans--were formulated for coating onto Nanopatch microprojections and applied to murine skin. Co-formulation with the stabilising disaccharides trehalose and sucrose protected virions during the dry-coating process. Transgene-specific CD8(+) T cell responses following Nanopatch delivery of both vectors were similar to intradermal injection controls after a single immunisation (despite a much lower delivered dose), though MVA boosting of pre-primed responses with Nanopatch was found to be less effective than the ID route. Importantly, disaccharide-stabilised ChAd63 could be stored for 10 weeks at 37°C with less than 1 log10 loss of viability, and retained single-dose immunogenicity after storage. These data support the further development of microprojection patches for the deployment of live vaccines in hot climates.

Indexed as

Adenoviruses, SimianGenetic VectorsVaccinia virusAnimalsChemistry, PharmaceuticalDermisEpidermisFemaleFreeze DryingMalaria VaccinesMiceT-LymphocytesTransgenesVaccine PotencyVaccines, AttenuatedVaccines, DNAMalaria VaccinesVaccines, AttenuatedVaccines, DNA

Identifiers

PMID23874462
PMCPMC3706440

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.